Top

Published in:

01-06-2018 | PHASE I STUDIES

Phase I study of the combination of quinacrine and erlotinib in patients with locally advanced or metastatic non small cell lung cancer

Authors: Priyanka Bhateja, Afshin Dowlati, Neelesh Sharma

Published in: Investigational New Drugs | Issue 3/2018

Summary

Introduction Preclinical data suggest quinacrine acts as an inhibitor of FACT (facilitates chromatin transcription) complex, which may play a role in TKI (tyrosine kinase inhibitor) resistance. The aim of this Phase I study was to study the safety and assess the maximum tolerated dose of quinacrine in combination with erlotinib in non small cell lung cancer (NSCLC). Methods This was a phase I study with standard 3 + 3 dose escalation design with the primary aim of determining the maximum tolerated dose. Two of 3 patients enrolled at dose level 1 experienced dose limiting toxicity (DLT). The next 6 patients were enrolled at dose level − 1 and none of these 6 patients experienced DLT. The dose of 50 mg of quinacrine every other day with 150 mg of erlotinib was established as the maximum tolerated and the recommended phase II dose. One of 3 patients treated at dose level 1 had stable disease. One of 6 patients treated at dose level − 1 had partial response for 6 months, the rest had progressive disease at the time of first assessment. Conclusion Combination of quinacrine and erlotinib was well tolerated but showed limited efficacy in advanced NSCLC.

Siegel RL, Miller KD, Jemal A (2017) Cancer Statistics, 2017. CA Cancer J Clin 67(1):7–30CrossRefPubMed

Scagliotti GV, Parikh P, von Pawel J et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26(21):3543–3551CrossRefPubMed

Favaretto AG, Pasello G, Magro C (2009) Second and third line treatment in advanced non-small cell lung cancer. Discov Med 8(43):204–209PubMed

Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353(2):123–132CrossRefPubMed

Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 2000;18(12):2354–2362. In

Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22(9):1589−1597. In

Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18(10):2095–2103. In

Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 373(17):1627–1639CrossRefPubMedPubMedCentral

Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 373(2):123–135CrossRefPubMedPubMedCentral

10.

Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13(3):239–246CrossRefPubMed

11.

Wu YL, Zhou C, Liam CK et al (2015) First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label. ENSURE study Ann Oncol 26(9):1883–1889

12.

Zhou C, Wu YL, Chen G et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12(8):735–742CrossRefPubMed

13.

Zhou C, Wu YL, Chen G et al (2015) Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol 26(9):1877–1883CrossRefPubMed

14.

Tumors Resistant to EGFR Inhibitors Can Arise via Different Mechanisms. Cancer Discov. 2016;6(3):228

15.

Galvani E, Sun J, Leon LG et al (2015) NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor. Oncotarget 6(40):42717–42732CrossRefPubMedPubMedCentral

16.

Jänne PA, Yang JC, Kim DW et al (2015) AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 372(18):1689–1699CrossRefPubMed

17.

Lin Y, Wang X, Jin H (2014) EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. Am J Cancer Res 4(5):411–435PubMedPubMedCentral

18.

Noda S (2016) Kanda S. Addressing epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer, Expert Rev Respir Med

19.

Sequist LV, Rolfe L, Allen AR (2015) Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med 373(6):578–579CrossRefPubMed

20.

Takezawa K, Pirazzoli V, Arcila ME et al (2012) HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov 2(10):922–933CrossRefPubMedPubMedCentral

21.

Wu SG, Liu YN, Tsai MF et al (2016) The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients. Oncotarget 7(11):12404–12414

22.

Bivona TG, Hieronymus H, Parker J et al (2011) FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. Nature 471(7339):523–526CrossRefPubMedPubMedCentral

23.

Dermawan JK, Gurova K, Pink J et al (2014) Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-κB, and cell-cycle progression in non-small cell lung cancer. Mol Cancer Ther 13(9):2203–2214CrossRefPubMed

24.

Cappuzzo F, Ciuleanu T, Stelmakh L et al (2010) Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11(6):521–529CrossRefPubMed

25.

Ciuleanu T, Stelmakh L, Cicenas S et al (2012) Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol 13(3):300–308CrossRefPubMed

26.

Coudert B, Ciuleanu T, Park K et al (2012) Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. Ann Oncol 23(2):388–394CrossRefPubMed

27.

Juhász E, Kim JH, Klingelschmitt G, Walzer S (2013) Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer. Eur J Cancer 49(6):1205–1215CrossRefPubMed

28.

Wu YL, Kim JH, Park K, Zaatar A, Klingelschmitt G, Ng C (2012) Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study. Lung Cancer 77(2):339–345CrossRefPubMed

29.

Cicènas S, Geater SL, Petrov P et al (2016) Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study). Lung Cancer 102:30–37CrossRefPubMed

30.

Gurova KV, Hill JE, Guo C et al (2005) Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci U S A 102(48):17448–17453CrossRefPubMedPubMedCentral

31.

Blakely CM, Pazarentzos E, Olivas V et al (2015) NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer. Cell Rep 11(1):98–110CrossRefPubMedPubMedCentral

32.

De S, Dermawan JK, Stark GR (2014) EGF receptor uses SOS1 to drive constitutive activation of NFκB in cancer cells. Proc Natl Acad Sci U S A 111(32):11721–11726CrossRefPubMedPubMedCentral

33.

Dubois EL (1954) Quinacrine (atabrine) in treatment of systemic and discoid lupus erythematosus. AMA Arch Intern Med 94(1):131–141CrossRefPubMed

34.

Engeset A (1958) Treatment of rheumatoid arthritis with quinacrine and chloroquine. Acta Rheumatol Scand 4(1):28–39CrossRefPubMed

35.

Plasma quinacrine concentration as a function of dosage and environment (1948) Joint Report of the Armoured Medical Research Laboratories and The Commission on Tropical Diseases, US Army. Arch Intern Med 78:65–106

36.

Looareesuwan S, Phillips RE, Edwards G et al (1988) Mepacrine accumulation during treatment of chloroquine-resistant falciparum malaria. Ann Trop Med Parasitol 82(2):107–112CrossRefPubMed

37.

Argiris A, Mittal N (2004) Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer. Lung Cancer 43(3):317–322CrossRefPubMed

38.

Gasparian AV, Burkhart CA, Purmal AA, et al. Curaxins: anticancer compounds that simultaneously suppress NF-κB and activate p53 by targeting FACT. Sci Transl Med. 2011;3(9 ):95ra74

39.

Dermawan JK, Hitomi M, Silver DJ et al (2016) Pharmacological targeting of the histone chaperone complex FACT preferential eliminates glioblastoma stem cells and prolongs survival in preclinical models. Cancer Res 76(8):2432–2442CrossRefPubMedPubMedCentral

40.

Sharma N, Dermawan J, Purmal AA, et al. Targeting FACT complex with CBL0137 to overcome acquired resistance to EGFR-TKI in lung adenocarcinoma. Cancer Res. 2016;76(14 Suppl): Abstract nr 3036

Title: Phase I study of the combination of quinacrine and erlotinib in patients with locally advanced or metastatic non small cell lung cancer
Authors: Priyanka Bhateja
Afshin Dowlati
Neelesh Sharma
Publication date: 01-06-2018
Publisher: Springer US
Published in: Investigational New Drugs / Issue 3/2018
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-017-0515-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 3/2018

Drug approval based on randomized phase 3 trials for relapsed malignancy: analysis of oncologic drugs granted accelerated approval, publications and clinical trial databases

Prognostic Implication of Inflammation-based Prognostic Scores in Patients with Intrahepatic Cholangiocarcinoma Treated with First-line Gemcitabine plus Cisplatin

Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial

A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer

The sirtuin 1/2 inhibitor tenovin-1 induces a nonlinear apoptosis-inducing factor-dependent cell death in a p53 null Ewing’s sarcoma cell line

Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results

Keynote webinar | Spotlight on antibody–drug conjugates in cancer